Under development by Sanofi-Aventis, Acomplia (rimonabant) is a selective CB1 endocannabinoid receptor antagonist indicated for the treatment of obesity.
It works by blocking endogenous cannabinoid binding to neuronal CB1 receptors. Activation of these receptors by endoegenous cannabinoids, such as anadamide, increases appetite. It is the most advanced endocannabinoid receptor antagonist in clinical development and offers a novel therapeutic approach to appetite control and weight reduction.
Obesity is now the most common nutritional disorder in western industrialised countries. Defined as a body mass index of greater than 30, it arises from the accumulation of excess fat in the body from over consumption of fatty foods. Prevalence of obesity in the US and Europe has reached epidemic levels.
Data from the World Health Organisation’s MONICA project show that in some parts of Europe over 70% of men aged 55-64 years are clinically obese or overweight (BMI >25) and almost 70% of women in this age group. One in five of all Americans is obese and one in three overweight. Furthermore, increasing rates of childhood obesity are likely to exacerbate the trend towards increasing obesity in adulthood.
Taranabant is the generic name given to a new trial medication being tested for the fight against obesity.
With obesity being such a huge problem in society today, there is a large demand for medications fighting it. And currently there is a new medication in the works which has been given the generic name Taranabant. There is still no official trademarked name for which Merck will most certainly obtain. It is still in the trial stages of development/testing but apparently Merck will apply to the FDA sometime 2008. What does this mean? Well that there could be shortly a new medication to fight obesity available in the US. Earlier in 2007, Rimonabant was voted against being recommended for the US. Although there are many other countries using it now.
The main problem with Acomplia is that is not manufactured by a US laboratory such as Merck so we think because of this that Sanofi has no chance to get brand Acomplia in the Us Market.
Acomplia works great.More and more people are satisfied with the results obtained with the generic version of Acomplia (Rimonabant).Its all about politics,even if Rimonabant works fine and is the first diet pill for long term usage its still not approved,we are talking about Big money here so FDA will wait for Merck 
In the quest to become lean, the new weight loss medication Taranabant is being tested to determine if the benefits are qualified enough to be put on the market. Currently (Jan 2008) the latest phase of testing is proceeding.
The latest study (phase 3) so far indicates that Taranabant indeed does help people lose weight. The people taking taranabant as apposed to the people taking the placebo did lose the most weight, even at lower doses Taranabant is appearing to be working which is quit surprising and could be very
beneficial in getting it approved for the market.
Both rimonabant and taranabant have their differences but with similarities as well. They target the CB-1 receptors in the body’s Endocannabinoid System which takes on many important tasks including things like food intake/anxiety/fear etc. To the general population, they work to reduce ones weight and cravings for food. What remains to be seen is once the final trials are performed for taranabant just how the side effects differ from rimonabant. There is also the possibility that in time the FDA reviews rimonabant again and deems it to be acceptable for the US population as many other countries around the world have. Only time will tell but things are looking fairly positive currently for Taranabant, we will see what happens in 2008 if Merck goes before the FDA.
There are two types of diabetes. Type 1 occurs when the body doesn’t produce any insulin. People with type 2 diabetes either don’t produce enough insulin or their cells ignore the insulin. Nearly 95% of people with diabetes have type 2.
Diabetes medicines are not as effective as diet and physical activity. However, your doctor might prescribe a diabetes medicine if you are at high risk for diabetes and have other medical problems, such as obesity, a high triglyceride level, a low HDL cholesterol level or high blood pressure.
A new drug to help people lose weight, rimonabant (brand named Acomplia), also helps people with type 2 diabetes shed pounds while improving their blood sugar levels, researchers say.
Rimonabant is being tested and is approved in Europe. However, it has not yet been approved for use in the United States. This finding suggests that rimonabant could be used as a new approach for treating diabetes where other drugs have failed.
“This is an interesting new class of drugs that probably offers something new and different to people with diabetes,” said Dr. Larry Deeb, president of medicine and science at the American Diabetes Association. He was not involved in the research.
In the study, Andre Scheen, from the University of Liege, Belgium, and colleagues looked at the effects of rimonabant in over 1,000 patients with poorly controlled type 2 diabetes. All the patients were obese or overweight and had failed treatment with other drugs.
The patients were given a low-calorie diet plan and advised to be more physically active. They were also given rimonabant at a dose of either 5 milligrams or 20 milligrams per day, or a placebo.
After a year, Scheen’s team found that patients taking rimonabant lost significantly more weight than those taking the placebo. Patients on placebo lost an average of 1.4 kilograms, compared with 2.3 kilograms for those given 5 milligrams per day and 5.3 kilograms in patients taking 20 milligrams per day. (For conversion, one kilogram is equal to just over 2 pounds.)
In addition, patients taking rimonabant had greater improvement in waist size, blood sugar control, cholesterol, and better appetite control, compared with patients receiving placebo, the researchers report.
“These findings support the use of 20 mg per day of rimonabant, in addition to diet and exercise, as a new approach to reduce body weight and improve blood glucose control as well as several other cardiovascular risk factors in overweight or obese patients with type 2 diabetes that was inadequately controlled by standard treatment,” the researchers concluded.
A new animal study on rimonabant (Acomplia / Zimulti) has identified yet one more possible health benefit for this controversial diet drug: it appears to reduce obesity-related liver damage that can lead to cirhossis of the liver.
A team of researchers led by Mohammed Bensaid of Sanofi-Aventis, the company that has developed rimonabant, reported on these latest developments in the July 2007 issue of Hepatology, the official journal of the American Association for the Study of Liver Diseases.
In their study involving liver function in obese rats, the researchers said they found that rimonabant reduced markers of liver damage, decreased levels of pro-inflammatory proteins, and improved lipid profiles.
Male obese rats were given rimonabant orally daily for 8 weeks and had their food intake monitored; control animals received the same amount of food as those receiving rimonabant.
The researchers reported the results showed treatment with rimonabant reduced liver enlargement, completely abolished hepatic steatosis, and decreased blood levels of enzyme markers that indicate liver damage.
It also strongly reduced levels of hepatic TNFa, a pro-inflammatory protein thought to induce insulin resistance in the liver and be involved in the progression of steatosis to hepatic fibrosis and cirrhosis.
It looks like that FDA is not in rush at all. Rimonabant acomplia has been approved for sale in Mexico since Nov. 9th. after couple of EU states /like UK/ this drug finally arrived to America. This diet pil is still not a available in all Mexican pharmacies. So highly anticipated diet drug even after two months of approval is not on the sale.
The impending sale of Acomplia in Mexico is clearly of interest to a number of potential American customers, who have decided they want to take the diet pill even though the U.S. Food and Drug Administration is months away from action on approval of the drug for sale in the United States.
The Acomplia is the first selective CB1 receptor blocker and has been approved for use anywhere in the world except USA.
The Rimonabant acomplia is famous by blocking chemical processes directly in the brain,which cause reduce appetite, help liver to burn more fat and it might be effective drug to cure smoking and even alcohol abuse. This drug might bring a new ways of healing obesity and additional health problems.
- You can buy drug in a country where Acomplia has been approved (ie, the France), the doctor will write out a prescription and you can take the prescription to a pharmacy, and buy the diet drug.
- You can buy Acomplia an online pharmacy i.e., the France). Usually, you will need to to fill out a brief medical form for review. Doctor will then decide whether to issue a prescription.
- Or you can contact an online pharmacy in Canada. procedure is the same as buying Acomplia from France, just waiting time and prices are lightly higher.
As the European Commission publicly said, you need to be carefull to buy unlicensed and counterfeit or illicit copies of rimonabant because you may be putting your health at risk.
Acomplia is the brand name of the medication while Rimonabant is the name of its active ingredient. Acomplia (Rimonabant), after its launch in the June 2006, has conquered a vast portion of weight loss drug market. This success of Rimonabant is the result of the benefits which it has given to numerous obese individuals in the European countries. After the UK, presently several other European countries are taking the benefits of Acomplia. Germany, Norway, Denmark, Ireland, Finland and Austria are those European nations where Sanofi-Aventis has already launched the sale of Rimonabant pills.
Rimonabant blocks the working of cannabinoid receptor type-1. This function of Rimonabant pill has great significance in control of appetite. Cannabinoid type-1 (CB-1) receptors are the messengers of coordination system of the human body. Their working enables the brain to know about various requirements of cells. Excess urge for food and urge for smoking are two harmful signals, which CB-1 receptors transfer to the brain. Regular use of Rimonabant pill keeps working of CB-1 receptors in control. The process not only controls excess urge for food but also the urge for smoking.
Diet pill Acomplia (Rimonabant) is available in two different volumes i.e. 10mg and 20mg. The general prescription volume of Rimonabant Acomplia is 20mg. In clinical tests and usages this volume of the medication is found to be very effective in control of appetite. This medication controls appetite efficiently only when taken on an empty stomach. An hour before breakfast is the ideal time to take Rimonabant diet pills. Swallow the pill of prescribed volume with a glassful of plain water daily. Try not to miss any dose, but if happens so; never try to compensate it by overdosing. Overdosing Rimonabant can be harmful for your health.
| |
Acomplia Diet Pill for drive obesity towards Slimness
|
| Acomplia diet pill is the true solution for drive your obesity towards slimness and smart body shape. As you all know that obesity can pull down your self-confidence, make your life sad, apart from making you a butt of everyone’s jokes. Now this is the time in which you must do something about your obesity. Acomplia diet pill is one of the most sorts out ways to deal with the sprite of obesity. Obesity is not only a health hazard on its own but also tags along many health risks as well like high blood pressure. Henceforth, it is essential to tackle obesity effectively and get rid from this disease as soon as possible. Acomplia rimonabant weight loss drug is an oral-prescription medication which was approved in UK only as an appetite suppressant and still on waiting for FDA approval in USA.
The works of acomplia rimonabant diet pill is simple to suppress appetite and hence loose weight. It works based on the simple principle of stimulating the hypothalamus gland, thereby influencing specific neuro-transmitters that are responsible for the intake of food in the body and also for fats. When these neuro-transmitters are targeted it causes condensed appetite or suppresses appetite. This implies that you would eat less than your normal appetite because you always feel fullness, which in turn would lead to reduce weight. To maximize the result of Acomplia diet pill, combine it with an appropriate fitness program and proper diet plan or balanced diet plan. |
|
Top Marketeer to Promote Taranabant, Competitor to Acomplia
Merck’s development of taranabant, a diet drug which has been described as a competitor for Acomplia (rimonabant), must be going pretty well because the pharmaceutical giant has brought back top marketeer Len Tacconi to serve as the drug’s global brand leader.
While taranabant, a cannabinoid-1 (CB-1) receptor inverse agonist that has a mechanism of action similar to that of Sanofi-Aventis’ rimonabant, is still in Phase III trials, it now appears that the Merck drug may well beat Acomplia to the U.S. market.
Merck continues to say little about taranabant, but Sanofi-Aventis withdrew its application to market Acomplia in the U.S. in June after an FDA advisory panel recommended against approving it due to concerns over psychiatric side effects.
Merck has said it intends to file for FDA approval of taranabant in 2008, and Sanofi — which continues to market rimonabant in Europe and some other countries — now is not expected to refile for the U.S.before the Merck filing.
Tacconi, who left Merck less than a year ago to become president of Discovery Health, spent a decade with Merck orchestrating high-spending consumer marketing campaigns for drugs that included Singulair, Zocor and Vioxx.
Before joining Merck, Tacconi had led North American marketing for Weight Watchers.
Pfizer is working on what has been called a cannabinoid receptor antagonist, called CP-945598, which also is in Phase III trials, but has not indicated when it hopes to file for FDA approval.
What has never been made totally clear is whether the Pfizer drug is a receptor antagonist, which would operate differently than the Sanofi and Merck drugs. Some researchers have expressed the belief that a true CB-1 antagonist could possible help in suppressing appetite while minimizing undesirable side-effects
While diet drug Acomplia (rimonabant) doubles the risk of depression, its benefits “continue to outweigh its risks” for overweight and obese individuals who are not taking antidepressants, European drug regulators concluded on July 19th.
But in deciding to let Acomplia remain on the market in Europe, the regulators expressed concern that “too many patients are taking Acomplia at the same time as antidepressants,” and issued a tougher warning to doctors to stop prescribing it to patients on antidepressants or suffering major depression.
The European Medicines Agency (EMEA) handed down their decision after reviewing safety data that led a U.S. FDA advisory panel last month to unanimously recommend against allowing rimonabant (also known as Zimulti) to be prescribed in the United States.
The EMEA’s Committee for Medicinal Products for Human Use (CHMP) said it asked Sanofi-Aventis following the FDA advisory panel meeting in June 2007 to “submit all available information on the psychiatric side effects of Acomplia.”
In assessing the data at its just concluded July meeting, the CHMP said it concluded “that the benefits of Acomplia continue to outweigh its risks, except in patients with ongoing major depression or taking antidepressants.”
But it added that the risk of depression is approximately doubled in all overweight and obese patients taking rimonabant, and the risk may be further increased in patients with a past history of depression.
“This increased risk is of concern, since Acomplia is now being used in patients with a history of psychiatric events,” the CHMP said. “In a small minority of cases, this could lead to suicidal ideation or even suicide attempts.”
The EMEA said that while doctors were warned when rimonabant was approved a year ago that they ” should not prescribe Acomplia in patients with uncontrolled serious psychiatric conditions such as major depression,” the warning will now be upgraded.
The CHMP said it is now recommending ” contraindicating Acomplia (rimonabant) from Sanofi-aventis, in patients with ongoing major depression or who are being treated with antidepressants, because of the risk of psychiatric side effects.
Under development by Sanofi-Aventis, Acomplia (rimonabant) is a selective CB1 endocannabinoid receptor antagonist indicated for the treatment of obesity.
“Acomplia is a selective CB1 endocannabinoid receptor antagonist.”
It works by blocking endogenous cannabinoid binding to neuronal CB1 receptors. Activation of these receptors by endoegenous cannabinoids, such as anadamide, increases appetite. It is the most advanced endocannabinoid receptor antagonist in clinical development and offers a novel therapeutic approach to appetite control and weight reduction.
The drug also has potential as a treatment for smoking cessation because the endocannabinoid system is involved in the body’s response to tobacco dependence.
Acomplia (rimonabant) has been available in Europe since the middle of 2006, following regulatory approval by the EMEA in June 2006 for its use as an adjunct to diet and exercise for obese or overweight patients with associated risk factors, such as type 2 diabetes or dyslipidaeamia. However, it has had a less easy passage through the US regulatory system.
Filed for approval with the FDA in April 2005, it has encountered significant delays over the past two years. In February 2007, the company learnt that the FDA had extended their decision on whether or not to approve Acomplia by a further 3 months. Despite the repeated setbacks, analysts remain optimistic that it will eventually be approved in the US as an aid to weight loss.
OBESITY PREDISPOSES TO SERIOUS ILLNESS
Obesity is now the most common nutritional disorder in western industrialised countries. Defined as a body mass index of greater than 30, it arises from the accumulation of excess fat in the body from over consumption of fatty foods. Prevalence of obesity in the US and Europe has reached epidemic levels.
Data from the World Health Organisation’s MONICA project show that in some parts of Europe over 70% of men aged 55-64 years are clinically obese or overweight (BMI >25) and almost 70% of women in this age group. One in five of all Americans is obese and one in three overweight. Furthermore, increasing rates of childhood obesity are likely to exacerbate the trend towards increasing obesity in adulthood.
here is a strong association between obesity and increased risk of cardiovascular disease and diabetes and possibly certain cancers, such as breast and colorectal cancer.
The dramatic rise in the incidence of type 2 diabetes is due largely to the increased prevalence of obesity. Increases in body weight lead to changes in blood lipid and cholesterol levels, predisposing to increased risk of atherosclerosis.
THERAPEUTIC APPROACHES TO TREATMENT OF OBESITY
Not surprisingly, the growing prevalence of obesity has stimulated the search for drugs to treat this condition. Various therapeutic strategies have been explored, including:
- Serotonin and noradrenaline reuptake inhibitors (anorectic agents)
- Lipase inhibitors
- ß 3-adrenoreceptor agonists
- Leptin agonists
- Melanocortin-3 agonists
Sanofi-Aventis’ approach is completely different to the above. It developed from the knowledge that cannabis smokers often experience extreme hunger pangs, which cannabis smokers refer to as “the munchies”. Sanofi-Aventis worked on the premise that if cannabinoids stimulate appetite, blocking cannabinoid receptors in the brain might reduce appetite.
The central cannabinoid (CB1) receptors are believed to play a role in controlling food consumption and the phenomena of dependence / habituation. To develop suitable drugs against this target, the human cannabinoid receptor was first cloned and then expressed in cells.
Compounds with potential inhibitory activity against this receptor were then screened for inhibitory activity. Rimonabant emerged from this screening process as a potent CB1 receptor antagonist. Preclinical animal studies subsequently showed that it could reduce consumption of fats and sugars, which contribute to weight gain.
Accomplia
Rimonabant diet treatment blocks circuitry in brain that gives body cravingsAcomplia Rimonabant ( accomplia ), is a new treatment which helps fat loss by helping people quit smoking and lose weight at the same time.
The in-development diet drug, rimonabant acomplia, which could be available in a year or two, works by an entirely new approach — by blocking the same primeval circuitry in the brain that gives pot-smokers the munchies.
Diet and weight loss Doctors who heard data on the new treatment said that while better living habits should still be the foundation of good health, a new treatment could be an important boost for those who cannot lose weight through willpower alone.
We tell people to diet and exercise, and that advice doesn’t seem to be very effective,” said Dr. Raymond Gibbons of the Mayo Clinic, who called the latest results ”very provocative.”
The French firm Sanofi-Synthelabo, which plans to seek U.S. approval to sell it under the brand Acomplia after more studies are finished next year.
Helped dieters drop 20 pounds in a year
One study found the drug helped people drop 20 pounds in a year, while the other concluded it doubles smokers’ success at quitting, at least in the short run. Doctors said the drug is likely to be marketed both for dieting and smoking cessation, but it is likely to be especially appealing to people beset by both problems.
”We think this might be the ideal compound for people who are overweight and smoke,” said Dr. Robert Anthenelli of the University of Cincinnati, who directed the smoking study.
Doctors say accomplia is also noteworthy because it takes a fresh approach to helping people overcome their yearning for food and tobacco. It is the first of a class of medicines that block the so-called endocannabinoid system.
Marijuana makes people ravenous by stimulating this circuitry. The same biological machinery serves crucial everyday purposes by helping the brain regulate hunger and probably other urges, including alcohol craving.
Overeating and smoking can overstimulate this system, which in turn propels people to eat and smoke still more. By temporarily blocking the body’s ability to receive these signals, experts believe they can return the system’s working to normal.
In the larger of the two studies, Dr. Jean-Pierre Despres of Laval University in Quebec City enrolled 1,036 overweight volunteers, all with big potbellies that put them at especially high risk of heart problems. They were urged to cut 600 calories a day and randomly given either rimonabant or dummy treatments.
Lost 10 percent of their body weight
After a year, those who got the higher of two doses of rimonabant had lost an average of 20 pounds and trimmed three inches from their waistlines. Nearly half of them took off 10 percent of their body weight. By comparison, those on placebos lost just five pounds.
Those getting rimonabant improved in other ways, too. Their levels of HDL, the protective good cholesterol, rose 23 percent, while their triglycerides fell 15 percent.
Despres said people taking the drug simply felt less hungry. In an earlier phase of the research, he could tell which volunteers were on the medicine by watching who passed up chocolate cake at the buffet table.
”The bottom line is we found a spectacular drop in waistlines and changes in many other risk factors that are beyond what you would ordinarily expect,” Despres said.
Anthenelli’s study tested the drug for 10 weeks on 787 pack-a-day smokers who wanted to quit but could not. A longer follow-up will see how well they stay off, but in the short run, 28 percent shunned cigarettes for at least a month, compared with 16 percent on dummy treatments.
Especially important for acomplia, Anthenelli said, is that those on the gained little or no weight, and a third of the successful quitters actually took off pounds of weight at the same time. Ordinarily, smokers gain six to 10 pounds when they quit.
Some people had minor digestive side effects at first, but they usually went away.
rimonabant(rimonabant cost) is the product launched by Sanofi-Aventis of France. This high efficacy appetite suppressant was launched in the UK anti-obesity drug market in the month of June. The drug is a ray of hope for million suffering from obesity. rimonabant cost has a chemical named Rimonabant which blocks the CB-1 receptor present in nerve cells. CB-1 receptor is the part of that mechanism which transmits hunger signals to the brain. Inhibiting working of CB-1 receptor means you will not feel enormous urge for food. In absence of food the metabolic system will burn the extra fats to get energy and an obese will get normal stature. buying, rimonabant can also curb urge for smoking.Using Rimonabant buying may have some mild initial side effects like nausea, constipation, stomach disorder and dizziness. Once the body is adjusted to the medication these problems disappear automatically. This is an oral prescription drug which must be taken on doctor’s advice.
buying rimonabant’s high efficacy in curbing dual problems i.e. obesity and smoking, therefore people are rushing for it. Sanofi-Aventis is planning to launch the drug in the US market after getting FDA approval for it.
Everyone knows that it’s the pharmaceutical industry’s job to come up with new products to cure what ails us. From Pfizer’s (NYSE: PFE) Lipitor to Eli Lilly’s (NYSE: LLY) Cialis, drugmakers have done a remarkable job of zeroing in on problems and finding treatments for them. It’s not too often, though, that pharmaceutical outfits develop medicine that addresses multiple conditions at once.Sanofi-Aventis (NYSE: SNY), though, may have done just that.The company intends to ask the Food and Drug Administration for approval to sell the drug rimonabant cost, which it plans to call rimonabant, within the next few months, the Associated Press reports. Sanofi-Aventis says that the drug allowed patients who took it for more than two years in trials to lose an average of 16 pounds. What’s more, most of the weight patients lost in the first year, they kept off.[rimonabant cost]
Of course, pharmaceutical outfits have ventured into the weight-loss field before, and it hasn’t always been pretty. Wyeth (NYSE: WYE), for instance, is still working to pay off the liability associated with the cardiovascular side effects of its fen-phen diet medication. Diet drugs on the market, meanwhile, are typically sold only for short-term use.
August 2, 2007
Sanofi-Aventis SA, the world’s third-largest pharmaceutical company, blamed competition from rivals’ generic copies of its blockbuster drugs and a weaker dollar on Wednesday as it posted a 6.3 percent decline in second-quarter profit.
LONDON, July 19, 2007-The European Medicines Agency (EMEA) today recommended contraindicating rimonabant structure (rimonabant) from sanofi-aventis, in patients with ongoing major depression or who are being treated with antidepressants, because of the risk of psychiatric side effects. Doctors in the EU have already been warned about this since June 2006 but the Agency’s Committee for Medicinal Products for Human Use (CHMP) has now recommended upgrading this warning.rimonabant structure has been authorised in the EU since June 2006 as an adjunct to diet and exercise for the treatment of obese or overweight adult patients. Psychiatric side effects, in particular depression, were identified as the main safety issue at the time of approval. They were reflected in the medicine’s product information as a warning that doctors should not prescribe rimonabant structure in patients with uncontrolled serious psychiatric conditions such as major depression.As part of its continuous monitoring of the safety of medicines, the CHMP requested sanofi-aventis in June 2007 to submit all available information on the psychiatric side effects of rimonabant structure. Finalising the assessment of the available data at its 16-19 July 2007 meeting, the CHMP concluded that the benefits of rimonabant continue to outweigh its risks, except in patients with ongoing major depression or taking antidepressants.
« Previous Entries
